ScreenerHero

ZTSZoetis Inc.

NYSE · US · Technology · Drug Manufacturers - Specialty & Generic · zoetis.com
77.73USDMkt Cap: 32.12B $P/E: 12.68

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the ani…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8
HIK
Hikma Pharmaceuticals PLC
$4.35BUSDP/E 12.7

Key Statistics

Company
Market Cap32.12B $
Enterprise Value38.58B $
Revenue (TTM)9.53B $
Gross Profit6.80B $
Net Income (TTM)2.67B $
Revenue/Share22.14 USD
Last Price77.73 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14.5K
CountryUS
SectorTechnology
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)12.68
P/E (Forward)11.28
PEG6.87
EV/EBITDA9.49
EV/Revenue4.05
P/S3.25
P/B9.57
EPS (TTM)6.13
EPS (Forward)6.65
52W Range
75.1875% of range78.59
52W High78.59 USD
52W Low75.18 USD
Profitability
Gross Margin71.84%
Oper. Margin40.72%
EBITDA Margin42.69%
Profit Margin28.23%
ROE80.25%
ROA17.28%
Growth
Revenue Growth-0.20%
Earnings Growth1.20%
Cash Flow & Leverage
Operating CF2.90B $
CapEx (TTM)621.00M $
FCF Margin21.18%
FCF Yield6.28%
Net Debt7.58B $
Net Debt/EBITDA1.86
Balance Sheet
Debt/Equity2.77
Current Ratio3.08
Quick Ratio1.57
Book Value/Sh7.839 USD
Cash/Share4.056 USD
Dividends
Fwd Div Rate2.120 USD
Trail. Div Rate2.060 USD
Div. Yield2.76%
5Y Avg Yield0.95%
Payout Ratio33.61%
Ex-Div DateJul 20, 2026
Pay DateSep 1, 2026
Analyst Consensus
Rating2.2 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)100.63 USD
Upside (mean)+29.5%
Target Range80.00 USD – 160.00 USD
$80.00+29.5% to mean$160.00
# Analysts16
Ownership
Shares Out.413.22M
Float412.37M
Insiders0.16%
Institutions100.21%
Short Interest
Short Ratio3.8d
Short % Float5.85%
Short % Out.5.17%
Shares Short21.35M
Short (prev mo.)15.92M
Technical
SMA 5076.15 (+2.1%)
SMA 200105.92 (-26.6%)
Beta0.73
S&P 52W Chg21.00%
Avg Vol (30d)5.05M
Avg Vol (10d)7.92M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—